SMN2 and proximal spinal muscular atrophy: Administered orally as a liquid formulation, it was approved by the FDA in 2020 for the treatment of SMA patients aged over two months and by the EMA in 2021 for patients with type 1, 2, or 3 SMA or 1–4 SMN2 copies at two months of age [38,39].